FDA Approves GSK RSV Vaccine for People Aged 60+--While still requiring ongoing Safety Monitoring

The U.S. Food and Drug Administration approved GlaxoSmithKline’s Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
------------------------------------
Join The Conversation! | https://trialsitenews.com/